Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3).

作者
Markus Moehler,Gunnar Folprecht,Volker Heinemann,Julian Walter Holch,Annett Maderer,Stefan Kasper,Susanna Hegewisch-Becker,Jan Schröder,Friedrich Overkamp,Frank Kullmann,Wolf O. Bechstein,Matthias Vöhringer,Robert Öllinger,Florian Lordick,Michael Geißler,Armin Schulz-Abelius,Bernhard Linz,Helga Bernhard,Andreas Paul,Irene Schmidtmann,Karin Potthoff,Carl C. Schimanski
出处
期刊:International Journal of Cancer [Wiley]
标识
DOI:10.1002/ijc.33881
摘要

Metastatic colorectal cancer (mCRC) patients with liver-limited disease (LLD) have a chance of long-term survival and potential cure after hepatic metastasectomy. However, the appropriate postoperative treatment strategy is still controversial. The CELIM and FIRE-3 studies demonstrated that secondary hepatic resection significantly improved overall survival. The objective of this analysis was to compare these favorable outcome data with recent results from the LICC trial investigating the antigen-specific cancer vaccine tecemotide (L-BLP-25) as adjuvant therapy in mCRC patients with LLD after R0/R1 resection. Data from mCRC patients with LLD and secondary hepatic resection from each study were analyzed for efficacy outcomes based on patient characteristics, treatment and surveillance after surgery. In LICC, 40/121 (33%) patients, in CELIM 36/111 (32%) and in FIRE-3-LLD 29/133 (22%) patients were secondarily resected, respectively. Of those, 31 (77.5%) patients in LICC and all patients in CELIM were R0 resected. Median disease-free survival after resection was 8.9 months in LICC, 9.9 months in CELIM. Median overall survival in secondarily resected patients was 66.1 months in LICC, 53.9 months in CELIM and 56.2 months in FIRE-3-LLD. Median age was about 5 years less in LICC compared to CELIM and FIRE-3. Secondarily resected patients of LICC, CELIM and FIRE-3 showed an impressive median survival with a tendency for improved survival for patients in the LICC trial. A younger patient cohort but also more selective surgery, improved resection techniques, deep responses and a close surveillance program after surgery in the LICC trial may have had a positive impact on survival. This article is protected by copyright. All rights reserved.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
阳光怀亦发布了新的文献求助50
1秒前
杜杜发布了新的文献求助10
4秒前
5秒前
123发布了新的文献求助10
6秒前
搜集达人应助活泼的行天采纳,获得10
7秒前
chen完成签到 ,获得积分10
7秒前
7秒前
linp发布了新的文献求助10
8秒前
LLL完成签到,获得积分10
9秒前
KDC完成签到,获得积分10
9秒前
阳光怀亦完成签到,获得积分10
10秒前
11秒前
呆瓜完成签到,获得积分10
11秒前
12秒前
12秒前
共享精神应助黑石采纳,获得10
13秒前
失眠的夏蓉完成签到,获得积分10
13秒前
13秒前
天天快乐应助潇湘雪月采纳,获得10
14秒前
胡图图发布了新的文献求助10
16秒前
平淡夜柳发布了新的文献求助10
16秒前
呆瓜发布了新的文献求助10
16秒前
研自助完成签到,获得积分10
17秒前
吊炸天完成签到,获得积分10
17秒前
123完成签到 ,获得积分10
19秒前
家家发布了新的文献求助30
19秒前
悲凉的大娘完成签到 ,获得积分10
20秒前
zhz完成签到,获得积分10
23秒前
24秒前
文静的立诚完成签到,获得积分10
24秒前
zhao发布了新的文献求助30
24秒前
家家完成签到,获得积分20
26秒前
王蔚染完成签到,获得积分10
26秒前
27秒前
PsyZP发布了新的文献求助10
28秒前
ao完成签到,获得积分10
28秒前
Blue发布了新的文献求助10
29秒前
illi完成签到,获得积分10
29秒前
31秒前
量子星尘发布了新的文献求助30
33秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989390
求助须知:如何正确求助?哪些是违规求助? 3531487
关于积分的说明 11254109
捐赠科研通 3270153
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809174